Overview
The Insurance Association of China recently released three draft model clauses for public comment: Short-term General Commercial Medical Insurance, Long-term General Commercial Medical Insurance, and City-customized Commercial Medical Insurance. The three cover contract composition, insurance liability, renewal and rate adjustment, consumer protection, and alignment with drug coverage lists.
This comes as commercial health insurance grows rapidly and DRG/DIP payment reform deepens—timing is ripe for unified industry rules. It is a key supply-side step toward normalization, one year after the “quality upgrade” guidance for health insurance.
Background & Interpretation
1. Regulatory and Industry Context
Previously, commercial medical policies differed in liability, renewal, and exclusions; some institutions used clause design for misleading sales, spurring claims disputes and hindering conversion of latent demand into active coverage. The model clauses unify standards at the source—clarifying terms like “reasonable and necessary” and “first diagnosis”—to raise real coverage value and protect consumers.
2. Core Drivers and Underlying Mechanism
Health insurance is shifting from “critical-illness-led, scale expansion” to “medical-insurance-based, value reconstruction.” In 2025, health premiums reached 997.3 billion yuan, with commercial medical insurance surpassing critical-illness for the first time; H1 2026 premiums were 643.8 billion yuan, +3.45% YoY. Under DRG/DIP cost control, commercial medical insurance must shoulder finer supplementary functions, and clause normalization is the prerequisite for a positive supply-demand loop.
3. Market Structure and Industry Chain Effects
The three clauses map to three directions: short-term covers current risk, long-term covers continuity, and city-customized (Huiminbao) links basic medical insurance with commercial cover to widen reach. Uniform standards shift industry focus from sales games to medical-resource integration, pricing-data accumulation, and an “insurance–medical–pharma” ecosystem, also enabling compliant embedding of AI health-management services.
Implications & Outlook
Near term, the clauses will improve readability and comparability of commercial medical contracts and cut misleading sales; medium term, product innovation should accelerate within the unified framework, with sub-segments like insurable-condition and mid-tier medical insurance expanding. Key variables are细则 pace, special-drug list alignment, and the regulatory stance on innovative products like participating critical-illness.
Takeaways for Industry Participants
Insurers should shift from clause maneuvering to professional capability—medical networks and data; consumers can compare coverage more clearly via standardized clauses; channels must adjust sales scripts and compliance. For investors, normalization is long-term positive for leading insurers’ product strength and reputation.
This column compiles industry information and shares technical perspectives; it does not constitute investment advice.